Delgocitinib

Delgocitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan. Among its listed roles, it functions as a anti-inflammatory drug, an antipsoriatic, an antiseborrheic and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a tertiary carboxamide, a nitrile, an azaspiro compound, a pyrrolopyrimidine, a N-acylazetidine and a tertiary amino compound. It is grouped under the following drug class(es): JAK inhibitors. Its therapeutic use is listed as anti-inflammatories and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Corectim and Anzupgo. Its PubChem CID is 50914062.

CAS No 1263774-59-9
Molecular Formula C16H18N6O
Molecular Weight 310.35 g/mol
Synonyms 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

Frequently Asked Questions